LT3820446T - Farmacinės kompozicijos, apimančios rpl554 hfa-134a terpėje, skirtos įvesti inhaliuojant - Google Patents

Farmacinės kompozicijos, apimančios rpl554 hfa-134a terpėje, skirtos įvesti inhaliuojant

Info

Publication number
LT3820446T
LT3820446T LTEPPCT/GB2019/052863T LTGB2019052863T LT3820446T LT 3820446 T LT3820446 T LT 3820446T LT GB2019052863 T LTGB2019052863 T LT GB2019052863T LT 3820446 T LT3820446 T LT 3820446T
Authority
LT
Lithuania
Prior art keywords
rpl554
hfa
inhalation
medium
pharmaceutical compositions
Prior art date
Application number
LTEPPCT/GB2019/052863T
Other languages
English (en)
Lithuanian (lt)
Inventor
Peter Lionel Spargo
Phillip A HAYWOOD
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Publication of LT3820446T publication Critical patent/LT3820446T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/GB2019/052863T 2018-10-09 2019-10-09 Farmacinės kompozicijos, apimančios rpl554 hfa-134a terpėje, skirtos įvesti inhaliuojant LT3820446T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1816447.5A GB2578093B (en) 2018-10-09 2018-10-09 Liquid pharmaceutical composition comprising RPL554 and HFA-134A
PCT/GB2019/052863 WO2020074894A1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation

Publications (1)

Publication Number Publication Date
LT3820446T true LT3820446T (lt) 2021-12-10

Family

ID=64394831

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/GB2019/052863T LT3820446T (lt) 2018-10-09 2019-10-09 Farmacinės kompozicijos, apimančios rpl554 hfa-134a terpėje, skirtos įvesti inhaliuojant

Country Status (27)

Country Link
US (2) US20210379053A1 (https=)
EP (2) EP3820446B1 (https=)
JP (2) JP7578587B2 (https=)
KR (1) KR20210073532A (https=)
CN (1) CN112912064B (https=)
AU (1) AU2019358585B2 (https=)
BR (1) BR112021006712A2 (https=)
CA (1) CA3113167A1 (https=)
CY (1) CY1124943T1 (https=)
DK (1) DK3820446T3 (https=)
ES (1) ES2899744T3 (https=)
GB (1) GB2578093B (https=)
HR (1) HRP20220053T1 (https=)
HU (1) HUE057780T2 (https=)
IL (1) IL282032B1 (https=)
LT (1) LT3820446T (https=)
MX (2) MX2021003599A (https=)
MY (1) MY207302A (https=)
PH (1) PH12021550767A1 (https=)
PL (1) PL3820446T3 (https=)
PT (1) PT3820446T (https=)
RS (1) RS62775B1 (https=)
SG (1) SG11202102567UA (https=)
SI (1) SI3820446T1 (https=)
SM (1) SMT202200044T1 (https=)
WO (1) WO2020074894A1 (https=)
ZA (1) ZA202102039B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3142701T3 (en) 2014-05-12 2018-08-13 Verona Pharma Plc New treatment
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201916915D0 (en) 2019-11-20 2020-01-01 Amr Centre Ltd Compounds
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024088364A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种包含异喹啉酮类化合物的药物组合物及其制备方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208310T3 (es) 1999-03-31 2004-06-16 Vernalis Limited Derivados de pirimido(6,1-a) isoquinolin-4-ona.
PH12013500261A1 (en) * 2010-08-09 2013-03-04 Verona Pharma Plc Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound
EP2819645A2 (en) * 2012-02-28 2015-01-07 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
EP2968313B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
DK3142701T3 (en) * 2014-05-12 2018-08-13 Verona Pharma Plc New treatment
CN110051627A (zh) * 2014-09-15 2019-07-26 维罗纳制药公司 包含rpl554的液体吸入制剂
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
DK3820446T3 (da) 2021-12-06
JP7578587B2 (ja) 2024-11-06
JP7836853B2 (ja) 2026-03-27
AU2019358585A1 (en) 2021-04-15
KR20210073532A (ko) 2021-06-18
MX2024001499A (es) 2024-02-27
BR112021006712A2 (pt) 2021-07-27
IL282032B1 (en) 2026-01-01
HRP20220053T1 (hr) 2022-04-15
SG11202102567UA (en) 2021-04-29
CN112912064A (zh) 2021-06-04
GB201816447D0 (en) 2018-11-28
AU2019358585B2 (en) 2025-01-16
US20250049781A1 (en) 2025-02-13
EP3820446B1 (en) 2021-11-03
GB2578093B (en) 2020-11-18
EP3960157A1 (en) 2022-03-02
US20210379053A1 (en) 2021-12-09
IL282032A (en) 2021-05-31
PT3820446T (pt) 2021-12-03
SI3820446T1 (sl) 2022-01-31
CA3113167A1 (en) 2020-04-16
EP3820446A1 (en) 2021-05-19
SMT202200044T1 (it) 2022-05-12
ES2899744T3 (es) 2022-03-14
JP2024113096A (ja) 2024-08-21
JP2022513566A (ja) 2022-02-09
CN112912064B (zh) 2025-02-14
MY207302A (en) 2025-02-15
RS62775B1 (sr) 2022-01-31
MX2021003599A (es) 2021-05-28
GB2578093A (en) 2020-04-22
PH12021550767A1 (en) 2021-10-04
HUE057780T2 (hu) 2022-06-28
ZA202102039B (en) 2022-08-31
WO2020074894A1 (en) 2020-04-16
CY1124943T1 (el) 2023-01-05
PL3820446T3 (pl) 2022-03-14

Similar Documents

Publication Publication Date Title
LT3820446T (lt) Farmacinės kompozicijos, apimančios rpl554 hfa-134a terpėje, skirtos įvesti inhaliuojant
FI3773495T3 (fi) Nikotiinipussikoostumus
DK3328843T3 (da) 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
DK3720418T3 (da) Nikotintablet
DK3362445T3 (da) Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed
LT3513809T (lt) Medicininė kompozicija, apimanti tivozanibą
PL3297605T3 (pl) Kompozycje farmaceutyczne do stosowania miejscowego
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
LT3405178T (lt) Formuluotės / kompozicijos, apimančios btk inhibitorių
PL3661373T3 (pl) Kompozycja farmaceutyczna na niedokrwistość
EA201791716A1 (ru) Фармацевтический состав
CL2020000212S1 (es) Inhalador.
EP3868371A4 (en) Novel pharmaceutical composition
EP3583943A4 (en) PHARMACEUTICAL COMPOSITION
EP3443854A4 (en) GESCHMACKSINHALATOR
LT3389633T (lt) Farmacinės kompozicijos, apimančios fenilaminopirimidino darinį
DK3908321T3 (da) Farmaceutisk sammensætning
DK4023651T3 (da) Optisk aktivt pyranochromenylphenolderivat og farmaceutisk sammensætning, der omfatter samme
EP3646867C0 (en) PHARMACEUTICAL COMPOSITION
CL2020000208E1 (es) Inhalador.
EP3463528A4 (en) INHALATORABSTANDSHALTER
EP3727485C0 (en) PHARMACEUTICAL COMPOSITION
EP4037741C0 (en) INHALATOR
EP3949952A4 (en) MEDICAL COMPOSITION
EP4032535A4 (en) PHARMACEUTICAL COMPOSITION